Abiopharma

🔍 Guarini Kathryn (Director)

Company: REGENERON PHARMACEUTICALS, INC. (REGN)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 400 shares of Common Stock at $719.37 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,003.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 400 shares of Common Stock at $800.0 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 603.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 400 shares of Non-Qualified Stock Option (right to buy) at $719.37 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2035-01-02 | equity_swap_involved: 0 | shares_owned_after: 1,558.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
• F2: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.